How often H. pylori comes back and what affects its return.
Official title: Recurrence of H Pylori : Incidence and Influential Factors in Sohag Government.
Run by Sohag University · NCT07045857 · Data updated 2026-11-12
This project will follow adults aged 18–75 who were treated for H. pylori to see how often the infection returns and which eradication regimens lower that risk.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Sohag University Academic / other |
| Locations | 1 site (Sohag) |
| Status | Recruiting |
| Started | May 13, 2025 |
| Main results expected | November 20, 2025 |
| Study ends | November 20, 2025 |
| Registry record updated | July 1, 2025 |
| Trial ID | NCT07045857 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–75 with a confirmed H. pylori infection who have received standard eradication therapy, have symptoms such as dyspepsia or peptic ulcer disease, and have normal liver, kidney, and blood test results.
✕Probably not a fit
Patients with recent use of proton pump inhibitors, H2 blockers, bismuth, or antibiotics within four weeks, active malignancy, severe unstable comorbidities, or recent significant gastrointestinal bleeding are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The study follows adults with confirmed H. pylori infection who completed medical eradication therapy and tracks them over time for recurrence. Participants will undergo periodic testing (urea breath test, stool antigen, or endoscopy/biopsy when indicated) and clinical assessments to document any return of infection. Investigators will collect data on the eradication regimen used, medication adherence, demographics, and comorbidities to identify factors associated with recurrence. The primary outcomes are recurrence rate and differences in recurrence between treatment approaches.
Why it matters
Potential benefit: If successful, the results could help doctors choose treatments and follow-up plans that reduce H. pylori coming back for future patients.
How similar studies have gone: Many prior studies have measured H. pylori recurrence and compared eradication regimens, so this approach is consistent with existing research though local results may vary.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age: 18-75 years old. * H. pylori infection: Confirmed by endoscopy, biopsy, or non-invasive tests (e.g., urea breath test, stool antigen test). * Symptoms: Presence of dyspepsia, peptic ulcer disease, or other H. pylori-related symptoms. * Laboratory tests: Normal liver and kidney function, and no significant abnormalities in blood counts. Exclusion Criteria: * Patients receiving eradication therapy in the past taking proton pump inhibitors,, H2 blockers ,,bismuth ,, antibiotics or other medications that interfere with the result of the examination in the recent 4 weeks. * Gastrointestinal disorders: Severe gastrointestinal disorders (e.g., gastric cancer, inflammatory bowel disease ,gastric or duodenal ulcer with current or recent bleeding , or clinical significant gastrointestinal bleeding within 4 weeks of randomization). * Malignancies: Active or recent malignancies. * Severe comorbidities: Unstable or severe comorbidities (e.g., heart failure, liver cirrhosis).
Where it's running
-
Sohag University Hospital
Sohag, Egypt Recruiting
Study contacts
- Study coordinator: Thomas W Thabet, Resident
- Email: thomaswagih0@gmail.com
- Phone: 01286046059
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Carminal for H. pylori gastritis
This trial will test if taking 30 ml daily of the Aloe vera–based supplement Carminal together with standard H. pylori therapy helps adults with H. pylori–positive gastritis heal their stomach lining better than standard therapy plus placebo.
-
Comparing vonoprazan-based dual and triple treatments with standard PPI triple therapy for H. pylori infection.
We're testing whether vonoprazan-based dual or triple treatments clear H. pylori more effectively than the usual PPI triple therapy in adults who have never been treated for the infection.
-
Registry for managing Helicobacter pylori infection in Argentina
This study collects information from doctors in Argentina to see how well different treatments work for Helicobacter pylori infections and to find the best ways to use antibiotics responsibly.
-
Eradicating H. Pylori with Argon Plasma During Endoscopy
This study is testing a new argon plasma treatment during endoscopy to see if it can safely get rid of H. pylori infections in patients who haven't been treated yet.
-
Screening and treating H. pylori to prevent gastric cancer in young adults
This study is testing if screening and treating young adults for H. pylori can help prevent gastric cancer in people aged 30-34 in several European countries.
-
Comparing H. pylori screening strategies to prevent gastric cancer
This project will test different ways to screen adults (age ≥20) for H. pylori who have never been screened or treated.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.